Friday, July 20, 6:24 AM
Alnylam Pharmaceuticals (ALNY) is in discussions with "more than one" potential partner to help it carry out Phase II and Phase III studies of its ALN-PCS treatment for high cholestoral, CEO John Maraganore says, although he declines to name names.
From Seeking Alpha.